title: Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
abstract: The majority of patients with subependymal giant cell astrocytoma (SEGA) have tuberous sclerosis complex (TSC). In such patients, the mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to induce responses. Isolated SEGA have been reported in patients without clinical or genetic features of TSC. The treatment of these patients with everolimus has not previously been reported. We treated a patient with a recurrent isolated SEGA with an mTOR inhibitor. The patient tolerated therapy well and had a sustained complete remission. MTOR inhibitors may be useful for the treatment of isolated SEGA. Further study is warranted.
authors.affiliation: Division of Pediatric Hematology and Oncology, Department of Paediatrics, The Children's Hospital at Saint Peter's University Hospital, New Brunswick, New Jersey.
authors.forename: Deepika
authors.initials: D
authors.lastname: Appalla
authors.affiliation: University Radiology, Saint Peter's University Hospital, New Brunswick, New Jersey.
authors.forename: Andres
authors.initials: A
authors.lastname: Depalma
authors.affiliation: Division of Pediatric Hematology and Oncology, Department of Paediatrics, The Children's Hospital at Saint Peter's University Hospital, New Brunswick, New Jersey.
authors.forename: Stanley
authors.initials: S
authors.lastname: Calderwood
mesh_terms: D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000201:enzymology; D002648:Child; D000068338:Everolimus / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D012074:Remission Induction; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014402:Tuberous Sclerosis
chemical_list: D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
keywords: biological response modifier; gliomas; low grade; rare tumors